^
Association details:
Biomarker:No biomarker
Cancer:Small Cell Lung Cancer
Drug:cisplatin (DNA synthesis inhibitor) +
topotecan (Topoisomerase I inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
04/14/2021
Excerpt:
Recommendations: Cisplatin with irinotecan or oral topotecan are alternative treatment options for SCLC patients[II, C].
DOI:
10.1016/j.annonc.2021.03.207